Skip to content
AnalystLens

Merck Annual Report, Year Ended Dec 31, 2018

Filing Date
Filed February 27, 2019
Period End
December 31, 2018
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Leadership change8-K · Oct ’22Oct ’22
  3. Leadership change8-K · Oct ’26Oct ’26

Summary

Summary of the 10-K filed February 27, 2019. Cited figures are marked; the original filing is the authoritative source.

Merck & Co., Inc. reported solid financial performance for the fiscal year ending December 30, 2018, with total sales reaching $42.3 billiona, a 5% increase over the previous year.

This growth was primarily driven by strong sales in the oncology segment, notably from Keytruda, and robust performance in vaccines, particularly Gardasil/Gardasil 9. The Animal Health division also contributed positively to the overall revenue increase. The company demonstrated a commitment to innovation through continued investment in its research and development pipeline, focusing on key areas like immuno-oncology.

Merck also actively pursued business development opportunities, including strategic collaborations and acquisitions, to enhance its portfolio and future growth prospects. The company returned significant capital to shareholders through dividends and share repurchases, reflecting its financial strength and confidence in its strategic direction. Despite facing ongoing pricing pressures and generic competition in certain product lines, Merck's diversified business segments and strong product pipeline position it for continued success.

Key Highlights

  1. Total sales increased by 5% to $42.3 billion in 2018, driven by strong performance in oncology (Keytruda), vaccines (Gardasil/Gardasil 9), and animal health.
  2. Keytruda sales significantly increased, reaching $7.2 billion in 2018, up from $3.8 billion in 2017, underscoring its importance as a growth driver.
  3. The company expanded its pipeline through collaborations and acquisitions, notably a strategic collaboration with Eisai for Lenvima and the acquisition of Viralytics.
  4. Research and development expenses remained substantial at $9.8 billion, reflecting continued investment in innovation and pipeline development.
  5. Merck returned $14.3 billion to shareholders in 2018 through dividends and share repurchases, demonstrating a commitment to shareholder value.
  6. The company faced continued pricing pressures globally and the impact of generic and biosimilar competition on certain established products, such as Zetia and Vytorin.
  7. The cyber-attack experienced in 2017 had a residual impact on sales in 2018, although it was less significant than in the prior year.

Financial Statements

FY2018 against FY2017

Line itemFY2018FY2017Change
Revenue$42.29B$40.12B+5.4%
Cost of Revenue$13.51B$12.78B+5.7%
Gross Profit$28.79B$27.35B+5.3%
R&D Expenses$9.75B$10.34B−5.7%
SG&A Expenses$10.10B$10.07B+0.3%
Interest Expense$772.00M$754.00M+2.4%
Net Income$6.22B$2.39B+159.8%
EPS (Basic)$2.34$0.88+165.9%
EPS (Diluted)$2.32$0.87+166.7%
Shares Outstanding (Basic)2.66B2.73B−2.4%
Shares Outstanding (Diluted)2.68B2.75B−2.5%

Frequently Asked Questions

  1. What were Merck's key drivers of sales growth in 2018?

    Merck's sales growth in 2018 was primarily driven by its oncology franchise, particularly Keytruda, which saw a significant increase in sales. The vaccines segment, led by Gardasil/Gardasil 9, also showed strong performance. The Animal Health division also contributed positively to the overall revenue growth.

  2. How is Merck investing in future growth?

    Merck continues to invest heavily in its research and development pipeline, with a focus on oncology and other key therapeutic areas. The company is also actively pursuing external innovation through strategic collaborations, such as the one for Lenvima with Eisai, and acquisitions, like that of Viralytics, to expand its product offerings and technological capabilities.

  3. What challenges did Merck face in 2018?

    Merck faced ongoing challenges including pricing pressures from healthcare cost containment efforts in various global markets, and the impact of generic and biosimilar competition on certain older products like Zetia and Vytorin, which led to sales declines in those areas. The lingering effects of the 2017 cyber-attack also impacted sales, albeit to a lesser extent than in the previous year.

  4. How did Merck's oncology portfolio perform?

    Merck's oncology portfolio was a major growth driver in 2018. Keytruda, the company's anti-PD-1 therapy, achieved significant sales growth, reaching $7.2 billion. The company also benefited from alliance revenue related to Lynparza and Lenvima, reflecting successful business development and expansion of its oncology offerings.